Understanding and preventing the impact of endocrine disruptors in sensitive populations
One of the first research projects to study endocrine disruptor chemicals' effects on the hypothalamus-pituitary axis
HYPIEND IN A NUTSHELL
Towards elucidating the health impacts of endocrine disrupting chemicals
Exposure to multiple Endocrine Disrupting Chemicals (EDCs) interferes with the function of the endocrine system, especially during developmental stages of life.
HYPIEND is one of the first projects to study EDCs effects on the hypothalamus-pituitary axis using a multidisciplinary approach, including preclinical models and two European-wide clinical studies.
The findings will be used to delineate interventional strategies for minimizing EDC exposure and consequences on the neuroendocrine system in pregnant and breastfeeding women and perinatal and pre-pubertal children.
PROJECT PHASES
A holistic approach to evaluate the effect of EDCs on the hypothalamus - pituitary axis
ALIGNED WITH USERS NEEDS
Committed to protect citizens from hazardous chemicals
According to a report from the Endocrine Society, since 2009 numerous international scientific and health organizations have raised concerns and took a public stance about the risks that EDCs pose for public health, and many have called for stronger regulations. Scientific community concerns led to several actions by the European Commission to improve its regulatory regime.
Adopted in 2018, the Comprehensive European Union Framework on Endocrine Disruptors defines the EU strategic approach on endocrine disruptors for the years to come.
In 2020, the European Union acknowledged the need for attention to EDCs and called for several specific actions, including a ban on several of these chemicals in consumer products in the Commission’s Chemicals Strategy for Sustainability.
In 2022, the EU Commission proposed new hazard classes under its chemicals regulation, including endocrine disruption, to better protect people and the environment from hazardous chemicals.
Under these regulatory frameworks and scientific concerns, HYPIEND aims at contributing to develop new endocrine disruptor screening methods and map out new public health strategies and policies to minimise the exposure of the most vulnerable populations.
STAY IN TOUCH
Be part of our community of interest!
Keep updated on the project progress and be the first to know about our latest results while you connect with other experts and citizens interested in endocrine disruptors.
NEWS & EVENTS
Check out our latest updates
Project news
HYPIEND research on bioanalysis of EDCs presented at the 15th BioDetectors Conference 2025
Ágata Llobet-Mut, HYPIEND partner from ProtoQSAR, presented the project’s computational strategies
HYPIEND presents EDC research on pregnancy and fetal health at HEAL Conference
Dr Alicja Baska, HYPIEND partner from CMKP/CPME presented the project at the Health and Environment Alliance (HEAL) international conference in Warsaw
HYPIEND’s cell-based screening toolbox for studying EDCs showcased to IIS La Fe PhD students
Elena García Lorente, researcher from HYPIEND partner Hospital Universitario La Fe (HULAFE), presented the project’s approach for studying EDCs health impacts
HYPIEND presented at the 71st Spanish Association of Paediatrics Congress
Paula Sol Ventura and Raquel Rodríguez, researchers at IGTP, carried on an oral presentation titled “Understanding and preventing the impact of endocrine disruptors in sensitive populations”
IGTP presents HYPIEND at the 47th Congress of the Foundation of the Spanish Society for Pediatric Endocrinology (FSEEP)
Paula Sol Ventura, researcher at IGTP, presented a poster titled “HYPIEND European Project: Understanding and preventing the impact of endocrine disruptors in vulnerable populations”
HYPIEND presented at the III Pediatric Environmental Health Day in Olot, Spain
HYPIEND partner Germans Trias i Pujol Research Institute (IGTP) presented the project at the III Jornada de Salut Mediambiental Pediàtrica
HYPIEND Platform for Behavioural Change Presented at Exposome Hub Seminar
Eurecat presented HYPIEND project behavioural-change platform, designed to provide recommendations for reducing everyday exposure to EDCs
A European study to analyse the impact of endocrine disruptors during pregnancy and the first 18 months of life
The research is part of the European project HYPIEND, coordinated by the Eurecat technology centre, and will be conducted simultaneously in Spain, Poland and Belgium with over 800 participants.
IGTP fosters interest in science among young students and presents HYPIEND at a science workshop fair in Badalona
Researchers from the HYPIEND partner IGTP took part in the third edition of “Ciència al carrer: Fira d’ESO amb mirada STEAM”
HYPIEND intervention studies presented at the Early Nutrition Symposium held by the Universitat Rovira i Virgili
Noemi Boqué (Eurecat) presented a poster on the HYPIEND intervention studies at the URV’s Early Nutrition Symposium 2025.
MEET THE TEAM
HYPIEND project consortium
HYPIEND is a collaborative consortium coordinated by Eurecat that involves the collaboration of research institutions and companies, collectively working towards a holistic understanding of EDC adverse health effects during critical development stages.
This Horizon Europe project brings together epidemiologists, exposure scientists, toxicologists, endocrinologists, health case practitioners, phycologists and risk assessors to bridge science-policy gaps.
List of partners
